Following clearance from the FDA, Hoth Therapeutics is carrying out a clinical trial as part of its open investigational new drug program for HT-001 in cancers undergoing toxicities from EGFR inhibition.
Cancer cells, malignant cells, generative ai illustration: © Dr_microbe - stock.adobe.com
Trial Name: A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
ClinicalTrials.gov Identifier: NCT05639933
Sponsor: Hoth Therapeutics, Inc.
Recruitment Contact: Hayley Springer, 646-756-2997, hayley@hoththerapeutics.com
Completion Date: January 29, 2025
The FDA has cleared the implementation of a number of protocol amendments for an ongoing trial evaluating HT-001 for the treatment patients with cancer undergoing treatment of skin toxicities associated with EGFRi, according to Holt Therapeutics, Inc.1
"We are extremely pleased to announce clearance of our clinical trial optimization plan for HT-001. Armed with positive initial data and a clean safety profile to date, we believe that these protocol amendments could ultimately result in the generation of a highly compelling data set which could support patients suffering from the effects of EGFRi cancer treatment. These latest developments underscore Hoth Therapeutics' continued commitment to delivering a safe and effective treatment for this very underserved patient population," said Robb Knie, chief executive officer of Hoth Therapeutics, in a press release.1
The randomized, double-blind, placebo-controlled, multicenter trial is being conducted under the IND for HT-001 by Hoth Therapeutics. The phase 2a trial is a dose-ranging study where investigators will assess the efficacy, safety, and tolerability of HT-001 for treatment of EGFRi-induced skin toxicity.
Patients aged 18 years and older who are receiving EGFRi therapy, have an estimated life expectancy ≥ 3 months, and have an ECOG performance status of 0-2 will be enrolled in 1 of 2 parallel cohorts and randomized to receive 1 of the 4 treatment arms.2 In part 1 of the trial, the open-label portion, 12 patients will be included and investigators will measure the pharmacokinetics of HT-001 gel. In part 2, the randomized, parallel arm study, 3 dose levels of HT-001 gel will be compared with placebo (HT-001 vehicle).
In both open-label and blinded cohorts of the study, all patients will apply the study drug to each of the affected areas once a day with cutaneous toxicity up to 30% body surface area involvement, inclusive of skin, scalp, and nails.
Determining the minimum efficacious dose strengths for further investigation serves at the main goal of the study. Dose effect, application site safety assessments, and therapeutic effects will also be evaluated based on the primary and secondary end points.
The trial has an estimated study completion date of January 29, 2025, and plans to enroll approximately 152 patients. Sites in Florida, Missouri, and Texas are actively recruiting patients.
FDA Grants Fast Track Designation to MVR-T3011 in HNSCC
March 20th 2024The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
Read More
Trilaciclib Advances in First-Line TNBC Treatment
February 21st 2024Following a favorable independent data monitoring committee review, the phase 3 PRESERVE 2 trial of trilaciclib in the first-line for patients with metastatic triple negative breast cancer treatment will move forward.
Read More
